These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 9892209)

  • 1. Elevation of cyclic adenosine 3',5'-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells.
    Chen T; Cho RW; Stork PJ; Weber MJ
    Cancer Res; 1999 Jan; 59(1):213-8. PubMed ID: 9892209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines.
    Putz T; Culig Z; Eder IE; Nessler-Menardi C; Bartsch G; Grunicke H; Uberall F; Klocker H
    Cancer Res; 1999 Jan; 59(1):227-33. PubMed ID: 9892211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP pathway.
    Wang X; Klein RD
    Mol Carcinog; 2007 Nov; 46(11):912-23. PubMed ID: 17427962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Essential role for G proteins in prostate cancer cell growth and signaling.
    Kue PF; Daaka Y
    J Urol; 2000 Dec; 164(6):2162-7. PubMed ID: 11061948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells.
    Lin J; Adam RM; Santiestevan E; Freeman MR
    Cancer Res; 1999 Jun; 59(12):2891-7. PubMed ID: 10383151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
    Xie Y; Wolff DW; Lin MF; Tu Y
    Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
    Cox ME; Deeble PD; Lakhani S; Parsons SJ
    Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutive activation of the 41- and 43-kDa mitogen-activated protein (MAP) kinases in the progression of prostate cancer to an androgen-independent state.
    Oka H; Chatani Y; Kohno M; Kawakita M; Ogawa O
    Int J Urol; 2005 Oct; 12(10):899-905. PubMed ID: 16323984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leuprorelin acetate affects ERK1/2 activity in prostate cancer cells.
    Iacopino F; Lama G; Angelucci C; Sica G
    Int J Oncol; 2006 Jul; 29(1):237-47. PubMed ID: 16773205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells.
    Altuwaijri S; Lin HK; Chuang KH; Lin WJ; Yeh S; Hanchett LA; Rahman MM; Kang HY; Tsai MY; Zhang Y; Yang L; Chang C
    Cancer Res; 2003 Nov; 63(21):7106-12. PubMed ID: 14612503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
    Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
    Siu SW; Lau KW; Tam PC; Shiu SY
    Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
    Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
    Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase A-Ialpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway.
    Alper O; Hacker NF; Cho-Chung YS
    Oncogene; 1999 Sep; 18(35):4999-5004. PubMed ID: 10490835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells.
    Skvortsova I; Skvortsov S; Stasyk T; Raju U; Popper BA; Schiestl B; von Guggenberg E; Neher A; Bonn GK; Huber LA; Lukas P
    Proteomics; 2008 Nov; 8(21):4521-33. PubMed ID: 18821526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guggulsterone-induced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase.
    Singh SV; Choi S; Zeng Y; Hahm ER; Xiao D
    Cancer Res; 2007 Aug; 67(15):7439-49. PubMed ID: 17671214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP.
    Engedal N; Korkmaz CG; Saatcioglu F
    Oncogene; 2002 Feb; 21(7):1017-27. PubMed ID: 11850819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S; Agoulnik IU; Weigel NL
    Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism.
    Sainz RM; Mayo JC; Tan DX; León J; Manchester L; Reiter RJ
    Prostate; 2005 Apr; 63(1):29-43. PubMed ID: 15378522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.